Preparations for Phase II clinical trials are moving along. The outstanding results accomplished during phase I trials in Europe and the U.S. provide a very good reason to be optimistic about the PLX-PAD product moving forward.

Recent funding accomplishments by Pluristem seem to make it clear that the company will be able to fund advancement rapidly without needing to attract a larger partner for shared financial participation. Often companies do need to wait for a participating partner before entering the next phase. This progress is HUGE, and it makes me optimistic that PSTI share prices will soon increase by many multiples and continue to grow over the coming year... we should pop with a resounding growth once the next clinicals are announced or maybe sooner.

Meanwhile, I'm planning to do more accumulating.

10Q due about 11-15-2010

GLTA